Cover Image

Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Tony Marchand, Cédric Pastoret, Gandhi Damaj, Angélique Lebouvier, Charles Herbaux, Aline Moignet, Miguel Pavlosky, Astrid Pavlosky, Anaise Blouet, Martin Eloit, Vincent Launay, Pierre Lebreton, Aspasia Stamatoullas, Christer Nilsson, Marlène Ochmann, Juliette Prola, Thierry Lamy
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	British Journal of Haematology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prognostic impact of valemetostat in relapsed/refractory adult T‐cell leukaemia‐lymphoma
by: Takafumi Shichijo, et al.
Published: (2025)

Elucidating novel immune profiles for predicting infection in high‐risk cohorts: a pilot study in patients with relapsed and refractory chronic lymphocytic leukaemia
by: Lewis J Williams, et al.
Published: (2025)

Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation
by: Francesca Perutelli, et al.
Published: (2025)

Teclistamab for relapsed refractory multiple myeloma patients on dialysis
by: P. Lebreton, et al.
Published: (2024)

Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post‐revumenib therapies
by: Miles Thomas, et al.
Published: (2025)

CAR‐DC combined with CAR‐T therapy for relapsed/refractory acute myeloid leukaemia: Research progress and future perspectives
by: Rui Zhang, et al.
Published: (2025)

Hypomethylating agent and venetoclax are effective salvage therapies in relapsed/refractory early T‐cell precursor acute lymphoblastic leukaemia
by: Vaibhav Agrawal, et al.
Published: (2025)

Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation
by: Alessandro Laganà, et al.
Published: (2024)

Establishing meaningful change thresholds for European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire CLL‐specific module domain scores: An analysis based on the TRANSCEND CLL 004 study in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma
by: Laurie Eliason, et al.
Published: (2024)

Cardoso el opositor académico VS. cardoso el político: ¿continuidad o ruptura?
by: Corinne Pastoret
Published: (2006)

Reseña de "Trade, Balance of Payments and Exchange Rate Policy in Developing Countries" de Anthony P. Thirlwall
by: Corinne Pastoret
Published: (2006)

Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab
by: Arnon P. Kater, et al.
Published: (2024)

Chronic lymphocytic leukaemia extravaganza: Vacuolated lymphoma cells
by: Radu Chiriac, et al.
Published: (2025)

Effects of temperature and browning on the functional response of a freshwater top predator
by: Viktor Nilsson‐Örtman, et al.
Published: (2026)

Venetoclax‐based non‐intensive combinations for relapsed/refractory acute myeloid leukaemia—Real‐world data from a UK ‐wide programme
by: Henry Wood, et al.
Published: (2025)

Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study
by: Gian Matteo Rigolin, et al.
Published: (2024)

Successful combined venetoclax to PD‐1 blockade and ruxolitinib for refractory Epstein–Barr virus‐associated haemophagocytic lymphohistiocytosis
by: Yue Song, et al.
Published: (2024)

A monstrous relapsed hairy cell leukaemia with large cells
by: Jérôme Paillassa, et al.
Published: (2024)

Lesbiennes, pédés, arrêtons de raser les murs
by: Eloit, Ilana, et al.
Published: (2024)

The effect of game-based exercise on infant acute lymphocytic leukaemia patients
by: Édgar Cortés-Reyes
Published: (2013)

Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype
by: Andrea Serafin, et al.
Published: (2025)

Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern era
by: Luani Barge, et al.
Published: (2025)

Pembrolizumab and pralatrexate for relapsed or refractory peripheral T‐cell lymphomas
by: Christina Poh, et al.
Published: (2026)

Treatment of refractory/relapsed Diamond–Blackfan anaemia with eltrombopag
by: Brynn B. Duncan, et al.
Published: (2024)

Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study
by: Yiling Ye, et al.
Published: (2025)

Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)—An open‐label, phase I/II study
by: Ivetta Danylesko, et al.
Published: (2025)

Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study
by: Elisabetta Petracci, et al.
Published: (2025)

Elaboración de la historia oral en Brasil. El proceso de transición visto a través de las historias de vida de los dirigentes políticos / Asp sia Camargo
by: Camargo, Aspásia
Published: (1985)

Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia
by: Tuan Hoang, et al.
Published: (2025)

Measurable residual disease‐driven treatment in first‐line chronic lymphocytic leukaemia
by: M. S. Davids, et al.
Published: (2024)

Topical ruxolitinib for facial blaschkitis in an adolescent
by: Diana H. Zarowin, et al.
Published: (2024)

Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma
by: Brendan Bender, et al.
Published: (2024)

Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis
by: Deevyashali Parekh, et al.
Published: (2024)

De‐diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria
by: Peter Johnstone, et al.
Published: (2025)

γδ and αβ T‐cell large granular lymphocytic leukaemia have similar characteristics and outcomes
by: Rui Cui, et al.
Published: (2024)

Endothelial activation and stress index ( EASIX ) as a biomarker to predict ruxolitinib failure for steroid‐refractory acute graft‐versus‐host disease treatment
by: Sergio Rodriguez‐Rodriguez, et al.
Published: (2025)

Single‐cell analysis reveals cytotoxic and memory CD8 + T cells associated with prolonged survival in relapsed/refractory leukaemia patients after haplo+cord haematopoietic stem cell transplantation
by: Hua Li, et al.
Published: (2026)

Varnimcabtagene autoleucel (ARI‐0001) in relapsed or refractory mantle cell lymphoma
by: Nil Albiol, et al.
Published: (2026)

Real‐world experience with CAR‐T therapy in relapsed and refractory follicular lymphoma
by: Nicolás Triantafilo, et al.
Published: (2025)

Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4‐positive peripheral T‐cell lymphoma and relapsed or refractory cutaneous T‐cell lymphoma: A post‐marketing surveillance in Japan
by: Kenji Ishitsuka, et al.
Published: (2024)